Drug facts

Semaglutide, pregnancy and birth control

By David Chen·Editor·Reviewed September 2026

Stop at least 2 months before a planned pregnancy¹

Section 8.3 of the Wegovy label says to discontinue it at least 2 months before a planned pregnancy, “to account for the long half-life of semaglutide.” The Ozempic label gives the same interval and calls the reason a long washout period. The Medication Guide puts it as simply as it can: stop using it 2 months before you plan to become pregnant.

Two months is a longer runway than many people expect from a once-weekly injection, so it is the number to plan around. For someone taking semaglutide for type 2 diabetes, the Ozempic Medication Guide adds a step: talk to the prescriber about the best way to control blood sugar before and during pregnancy.⁴

How long semaglutide stays in your body²

The two-month figure comes from the drug’s pharmacokinetics. The label gives semaglutide an elimination half-life of about 1 week, and says it will be present in the circulation for about 5 to 7 weeks after the last injected dose of 2.4 mg or 7.2 mg. Two months covers that window with a little to spare.

That is also why the last dose is not the end of exposure. A pregnancy that starts two weeks after stopping still starts with semaglutide in the bloodstream.

Semaglutide and birth control⁴

Neither semaglutide label mentions contraception by name, and neither tells you to switch from the pill to another method or to add a backup method. If you have read that advice about a weight-loss injection, it did not come from the Wegovy or Ozempic label.

What the labels do contain is a direct test. The Ozempic label reports a study of a combined oral contraceptive (ethinylestradiol with levonorgestrel) given with semaglutide 1 mg at steady state. It found no clinically relevant interaction and says no dose adjustment is needed. The Wegovy label reports the same for ethinyl estradiol and levonorgestrel taken alongside the semaglutide tablet: no clinically significant difference in how the body handled them.²

The general caution still applies. Section 7.2 says semaglutide delays gastric emptying and so has the potential to affect how oral medicines are absorbed. In clinical pharmacology trials with the 1 mg injection it did not, but the label asks prescribers to monitor the effects of oral medicines taken with it.³

In practice that makes birth control a conversation with the prescriber rather than a rule on the label, especially while doses are rising and stomach side effects are most common. Other oral medicines are covered on semaglutide interactions.

If you become pregnant⁵

For weight reduction or cardiovascular risk reduction, the Wegovy label says to discontinue semaglutide when pregnancy is recognized. Its reason is direct: weight loss offers no benefit to a pregnant patient and may cause fetal harm. The label also notes that appropriate weight gain during pregnancy is recommended for everyone, including people who started with overweight or obesity.

Two indications are treated differently. For liver disease (MASH), Wegovy should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Ozempic, used for type 2 diabetes, carries the same benefit-and-risk wording, because poorly controlled diabetes in pregnancy carries its own risks.⁴

What the evidence is⁵

The label describes the human data from pharmacovigilance and clinical trials as insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse outcomes. The concern comes from animal studies: in rats, rabbits and monkeys given semaglutide during organogenesis, the label reports early pregnancy losses and structural abnormalities at clinically relevant exposures, alongside marked weight loss in the mothers.

“Insufficient to establish” is not “shown to be safe.” The instruction to stop follows from the animal findings plus the lack of human data, not from a proven harm in people. For context, the label gives the background risk in the general US population as 2% to 4% for major birth defects and 15% to 20% for miscarriage in clinically recognized pregnancies.

The pregnancy registry⁵

A pregnancy exposure registry monitors outcomes in women exposed to Wegovy during pregnancy, and the label encourages both patients and healthcare providers to contact it. It exists because the human data are thin. Breastfeeding after delivery has its own page: semaglutide and breastfeeding.

This page reports the approved label, and a compounded preparation is not exempt from any of it. Decisions about pregnancy, birth control and your own dose belong with your prescriber. See the medical disclaimer.